Pacira's Gene Therapy PCRX-201 Hits Manufacturing Milestone, ASCEND Data Due Year-End
PCRX sits 38% above its 52-week low of $18.8.
Summary
Pacira's gene therapy candidate PCRX-201 has successfully transitioned to a scalable commercial manufacturing process, a critical step toward potential commercialization. The Part A enrollment in the ASCEND study is now complete, with topline data expected by the end of 2026. This progress comes amid a heated proxy battle with activist investor DOMA Perpetual, where the company's pipeline execution is a central point of contention. The manufacturing milestone de-risks the program and strengthens management's hand ahead of the shareholder vote. The upcoming ASCEND data readout will be a major catalyst for the stock.
At the time of this announcement, PCRX was trading at $26.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.